TP53 and neoplasm: We hypothesise that UBC overexpression may function as a driving oncogenic event in recurrence by promoting the degradation of key tumour suppressor proteins (e.g., components of the p53 signalling pathway, which is significantly enriched in our data), thereby enhancing tumour cell survival and treatment resistance.